Xenon Pharmaceuticals' Azetukalner Achieves Phase 3 Success in Epilepsy Trial, Boosting Blockbuster Potential

on

Xenon's Phase 3 X-TOLE2 trial of azetukalner for focal onset seizures met its primary endpoint, with a -53.2% median reduction in monthly seizure frequency for the 25 mg dose vs. -10.4% for placebo123.

Key secondary endpoint met:
54.8% of 25 mg patients and 37.6% of 15 mg patients had ≥50% seizure reduction vs. 20.8% placebo1.

Results described as exceeding expectations with highest placebo-adjusted efficacy in pivotal epilepsy studies; stock surged ~45% to over $6012.

Safety profile consistent with prior studies; common AEs:
dizziness (20.5%), headache (8.8%); discontinuation 14.5% in 25 mg group1.

NDA submission to FDA planned for Q3 2026; first-in-class KV7 potassium channel opener also in Phase 3 for MDD and bipolar depression12.

Sources:

1. https://www.investing.com/news/company-news/xenons-epilepsy-drug-azetukalner-meets-phase-3-trial-goals-93CH-4549327

2. https://www.biospace.com/drug-development/xenon-to-seek-approval-of-first-in-class-epilepsy-drug-after-exceeding-phase-3-expectations

3. https://news.futunn.com/en/post/69810831/xenon-pharmaceuticals-opened-with-a-surge-as-its-epilepsy-drug